Christophe Massard

24.4k total citations · 4 hit papers
432 papers, 12.6k citations indexed

About

Christophe Massard is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Christophe Massard has authored 432 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 245 papers in Pulmonary and Respiratory Medicine, 239 papers in Oncology and 114 papers in Cancer Research. Recurrent topics in Christophe Massard's work include Prostate Cancer Treatment and Research (110 papers), Cancer Immunotherapy and Biomarkers (91 papers) and Cancer Genomics and Diagnostics (72 papers). Christophe Massard is often cited by papers focused on Prostate Cancer Treatment and Research (110 papers), Cancer Immunotherapy and Biomarkers (91 papers) and Cancer Genomics and Diagnostics (72 papers). Christophe Massard collaborates with scholars based in France, United States and United Kingdom. Christophe Massard's co-authors include Jean‐Charles Soria, Karim Fizazi, Yohann Loriot, Antoine Hollebecque, Aurélien Marabelle, Stéphane Champiat, Charles Ferté, Samy Ammari, Éric Deutsch and Bernard Escudier and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Christophe Massard

408 papers receiving 12.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

2016 867 citations Stéphane Champiat, Laurent Dercle et al. Clinical Cancer Research profile →
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

2018 825 citations Laurent Dercle, Stéphane Champiat et al. The Lancet Oncology profile →
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

2016 409 citations Christophe Massard et al. profile →
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

2019 272 citations Jean‐Marie Michot, Ariane Laparra et al. profile →

Peers

Countries citing papers authored by Christophe Massard

Since Specialization

Citations

This map shows the geographic impact of Christophe Massard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Massard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Massard more than expected).

Fields of papers citing papers by Christophe Massard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Massard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Massard. The network helps show where Christophe Massard may publish in the future.

Co-authorship network of co-authors of Christophe Massard

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Massard. A scholar is included among the top collaborators of Christophe Massard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Massard. Christophe Massard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors 2025 ·Cancer ·Timothy A. Yap, Olivier Rixe, Capucine Baldini, Ursa Brown‐Glaberman, (unknown), David S. Hong, Christophe Massard, Jameel Muzaffar, Andreea Varga, Emrullah Yilmaz, (unknown), (unknown), Yi Liu, Matthew Hruska, Henry Zhao, (unknown), Solmaz Sahebjam	2
2	Innovative, early-phase clinical trials of drug–radiotherapy combinations 2025 ·The Lancet Oncology ·Antonin Lévy, Christophe Massard, Stefan Michiels, Éric Deutsch	3
3	From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug development 2025 ·ESMO Open ·Stéphane Champiat, (unknown), Ariane Laparra, Andreas Charalambous, Mario Di Palma, Karin Jordan, Christophe Massard, Matti Aapro, (unknown)	0
4	Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer 2023 ·Clinical Genitourinary Cancer ·Nobuaki Matsubara, Johann S. de Bono, Christopher Sweeney, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Josep Garcia, Geng Chen, Adam Harris, (unknown), Rucha Sane, (unknown), Sergio Bracarda, Cora N. Sternberg	5
5	Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias 2022 ·Cancer Treatment Reviews ·Maria Kfoury, (unknown), (unknown), Anne-Laure Voisin, Stéphane Champiat, Jean‐Marie Michot, Salim Laghouati, Caroline Robert, Benjamin Besse, Jean‐Charles Soria, Olivier Lambotte, Christophe Massard, Aurélien Marabelle, Matthieu Texier	35
6	Interventional Radiology for Local Immunotherapy in Oncology 2021 ·Clinical Cancer Research ·Lambros Tselikas, Stéphane Champiat, Rahul A. Sheth, (unknown), Samy Ammari, Frédèric Deschamps, Siham Farhane, Charles Roux, Sandrine Susini, Séverine Mouraud, Alexandre Delpla, (unknown), Caroline Robert, Christophe Massard, Fabrice Barlési, Jean‐Charles Soria, Aurélien Marabelle, Thierry de Baère	26
7	Impact de l’utilisation de la corticothérapie systémique sur l’efficacité des inhibiteurs de points de contrôle immunitaire 2021 ·Bulletin du Cancer ·(unknown), Maria Kfoury, Pernelle Lavaud, Aurélien Marabelle, Stéphane Champiat, Nawfel Mellas, Benjamin Besse, Christophe Massard, Arthur Géraud	1
8	TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials 2021 ·Cancers ·Elise F. Nassif, Édouard Auclin, Rastilav Bahleda, Charles Honoré, Olivier Mir, Sarah Dumont, Benoîte Méry, (unknown), Mehdi Brahmi, Olivier Trédan, Isabelle Ray‐Coquard, Jean‐Yves Blay, Christophe Massard, Axel Le Cesne, Armelle Dufresne	7
9	Impact of aging on immune-related adverse events generated by anti–programmed death (ligand)PD-(L)1 therapies 2020 ·European Journal of Cancer ·Capucine Baldini, P. Martin Romano, Anne-Laure Voisin, François‐Xavier Danlos, Stéphane Champiat, Salim Laghouati, Maria Kfoury, H. Vincent, Sophie Postel‐Vinay, Andreea Varga, Perrine Vuagnat, Vincent Ribrag, Laura Mezquita, Benjamin Besse, Antoine Hollebecque, Olivier Lambotte, Jean‐Marie Michot, Jean‐Charles Soria, Christophe Massard, Aurélien Marabelle	63
10	Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT) 2020 ·Clinical Cancer Research ·Martin Smoragiewicz, Alex A. Adjei, Emiliano Calvo, Josep Tabernero, Aurélien Marabelle, Christophe Massard, Jun Tang, Elisabeth G.E. de Vries, Jean-Yves Douillard, Lesley Seymour	5
11	Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors 2019 ·Clinical Cancer Research ·Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, Yohann Loriot, Ken A. Olaussen, Christophe Massard, Luc Friboulet	88
12	First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy 2019 ·SHILAP Revista de lepidopterología ·Pamela N. Münster, Monica Mita, Amit Mahipal, John Nemunaitis, Christophe Massard, Tom Mikkelsen, Cristina Cruz, Luis Paz‐Ares, Manuel Hidalgo, Dana E. Rathkopf, (unknown), (unknown), Barbara Eichhorst, Timothy F. Cloughesy, (unknown), Li S, Heather K. Raymon, (unknown), Kristen Hege, (unknown)	1
13	Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss 2018 ·Clinical Cancer Research ·Johann S. de Bono, Ugo De Giorgi, Daniel Nava Rodrigues, Christophe Massard, Sergio Bracarda, Albert Font, Jóse Ángel Arranz Arija, Kent C. Shih, George Daniel Rădăvoi, Na Xu, Wai Yee Chan, Han Ma, Steven Gendreau, Ruth Riisnaes, Premal H. Patel, Daniel Maslyar, Viorel Jinga	227
14	Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation 2018 ·Clinical Cancer Research ·Marie-Léa Gauci, Émilie Lanoy, Stéphane Champiat, Caroline Caramella, Samy Ammari, Sandrine Aspeslagh, Andréa Varga, Capucine Baldini, Rastilav Bahleda, Anas Gazzah, Jean‐Marie Michot, Sophie Postel‐Vinay, Eric Angevin, Vincent Ribrag, Antoine Hollebecque, Jean‐Charles Soria, Caroline Robert, Christophe Massard, Aurélien Marabelle	106
15	ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer 2018 ·European Urology Focus ·Katriina Peltola, Petri Bono, Robert H. Jones, Egils Vjaters, Pirjo Nykänen, Annamari Vuorela, Riikka Oksala, Pasi Pohjanjousi, Mika Mustonen, Karim Fizazi, Christophe Massard	5
16	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 breakdown → 2016 ·Clinical Cancer Research ·Stéphane Champiat, Laurent Dercle, Samy Ammari, Christophe Massard, Antoine Hollebecque, Sophie Postel‐Vinay, Nathalie Chaput, Alexander M.M. Eggermont, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté	867
17	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations 2016 ·Cancer Research ·Yu Fu, Cécile Jovelet, Thomas Filleron, Marion Pedrero, Nelly Motté, Yannick Boursin, (unknown), Christophe Massard, Mario Campone, Christelle Lévy, Véronique Dièras, Thomas Bachelot, Julie Garrabey, Jean‐Charles Soria, Ludovic Lacroix, Fabrice André, Céline Lefèbvre	11
18	Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey 2014 ·European Journal of Cancer ·Xavier Paolettí, Christophe Le Tourneau, Jaap Verweij, Lillian L. Siu, Lesley Seymour, Sophie Postel‐Vinay, Laurence Collette, Elisa Rizzo, S. Percy Ivy, David Olmos, Christophe Massard, Denis Lacombe, Stan B. Kaye, Jean‐Charles Soria	60
19	Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials 2013 ·Clinical Cancer Research ·Charles Ferté, (unknown), Antoine Hollebecque, Serge Koscielny, Antonin Lévy, Christophe Massard, (unknown), Brian M. Bot, Carlos Gomez‐Roca, Clarisse Dromain, Samy Ammari, Jean‐Charles Soria	130
20	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials 2011 ·Clinical Cancer Research ·David Olmos, Richard D. Baird, Timothy A. Yap, Christophe Massard, Lorna Pope, Shahneen Sandhu, Gerhardt Attard, Juliet Dukes, Dionysis Papadatos-Pastos, (unknown), Stan B. Kaye, Johann S. de Bono	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact